The effect of intrinsic sympathomimetic activity on platelet aggregation and fibrinolytic activity

Publisher Website
Google Scholar
Abstract
Bopindolol, a new β-blocking agent with intrinsic sympathomimetic activity, given orally at a dose of 1 mg twice a day, was as efficacious as propranolol at 80 mg twice a day, in a controlled double-blind trial on 12 hypertensive patients. Bopindolol did not depress cyclic AMP (cAMP) below the natural level, while propranolol depressed cAMP by 20%. Two clinically relevant biochemical parameters known to be influenced by cAMP were correspondingly affected by propranolol, which increased the aggregability of platelets induced by adenosine diphosphate, and diminished the fibrinolytic activity. Neither of these unwanted effects occurred with bopindolol treatment.

This publication has 0 references indexed in Scilit: